RePORT India Partners: 

  • Bhagawan Mahavir Medical Research Centre, Hyderabad
  • Byramjee Jeejeebhoy Government Medical College (BJGMC), Pune
  • Boston Medical Center, Boston, Massachusetts
  • Christian Medical College (CMC), Vellore
  • Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry
  • Johns Hopkins University, Baltimore, Maryland
  • National Institute for Research in Tuberculosis (NIRT), Chennai
  • University of Texas (UTX) Health Science Center, Tyler, Texas
  • University of Washington/University of Cambridge

Lead Investigator:

Vidya Mave

This clinical trial is evaluating the safety and efficacy of a new recombinant BCG vaccine, VPM1002, in preventing TB recurrence among former pulmonary TB patients who have successfully completed first line anti-TB treatment (ATT) and were declared cured. 

Resource Type:
Research Studies
Media Type: